Pharmaceutical Technology's In the Lab eNewsletter
Sartorius introduced the Cubis II portfolio of laboratory balances at Pittcon 2019 in Philaphelia, PA.
Sartorius’ Cubis II portfolio of balances for R&D and analytical laboratories offer high capacity, readability, and robust stability and accuracy for all sample types. Configurable hardware and software are fully customizable to maximize operational efficiency and experimental outcomes.
Features include the following:
The balances promote intuitive operation aided by intelligent diagnostic systems. This enables increased repeatability of workflows while lowering the possibility of human error during measurement steps, according to the company. Standard operating procedures can be configured as an approved workflow.
Gerry Mackay, member of the executive board, Sartorius Lab Products and Services division, stated in a March 19, 2019 press release that the Cubis II series integrates seamlessly into existing workflows unlike universal balances, which may require a lab’s standard operating procedures to be adapted to the functionality of the balance.
The Cubis II portfolio was introduced at Pittcon 2019 in Philadelphia, PA, which runs from March 19¬–21, 2019.
Source: Sartorius
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.